Intracameral mydriatic delivery: simplifying the process


Intracameral mydriatic delivery greatly simplifies cataract surgery.

Intracameral mydriatic delivery greatly simplifies cataract surgery, according to Anders Behndig and colleagues from Umeå University Hospital, Sweden, speaking at the update on drug delivery systems symposium.

Dr Behndig noted that topical administration of cyclopentolate and metaoxedrine as a regimen for mydriasis prior to a cataract procedure has some putative disadvantages, including slow penetration through the cornea resulting in a slow onset of the mydriatic effect and an increased risk of cardiovascular side effects. In addition, topically administered mydriatics tend to wear off during the operation.

Dr Behndig and his team tested an alternate mydriatic regimen using intracameral (ICM) injection mixed with lidocaine given at the start of the procedure. A cocktail of cyclopentolate 0.1%, phenylephrine 1.5% and xylcaine 1% was initially used, however the team later discovered that cyclopentolate could be omitted to provide a shorter duration for the mydriatic effect.

This new method reduces preoperative waiting time as well as reducing doses of the mydriatic drugs, thereby lowering the risk of systemic side effects. Using ICM, the pupils reach 95±3% of their maximum size within 20 seconds after injection. Although the average initial pupil size is slightly smaller compared to that achieved with topical mydriatics, the ICM pupils continue to enlarge throughout the procedure, unlike topical mydriatic pupils, which generally contract.

Furthermore, ICM does not induce any additional inflammation or corneal endothelial cell loss, does not increase the surgical time or complication rates and does not impose any cardiovascular risk. ICM can also be used to re-dilate pupils that contract during surgery, which is particularly beneficial for patients with floppy-iris syndrome.

After using ICM in several thousand patients since 2003, Dr Behndig believes it is an effective and safe method for mydriasis and greatly simplifies cataract surgery routines.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.